The mean that defines success at the final analysis. Typically chosen to be the minimal detectable difference, i.e. the critical on the scale of the effect size of interest corresponding to the significance level at the final analysis.
Rufibach, K., Jordan, P., Abt, M. (2016a).
Sequentially Updating the Likelihood of Success of a Phase 3 Pivotal Time-to-Event Trial based on Interim Analyses or External Information.
J. Biopharm. Stat., 26(2), 191--201.